Synageva Biopharma Corp. Announces Latest Public Offering

January 13, 2015

Firm advises underwriters, led by Goldman, Sachs & Co., in $308 million offering of clinical stage biopharmaceutical company Synageva’s common stock. 

Synageva BioPharma Corp. recently announced that it has closed on its $308 million public offering of 3,450,000 shares of common stock.  Willkie represented the underwriters, led by joint book-running managers Goldman, Sachs & Co. and J.P. Morgan Securities LLC, in the transaction.  Massachusetts-based Synageva is a clinical stage biopharmaceutical company developing therapeutic products for life-threatening rare diseases.  The deal was handled by partners Gregory Astrachan, Benjamin Nixon and Thomas Meloro; of counsel Martin Miller and associate Bonnie Tice.